Vanguard Fiduciary Trust
REGN icon

Vanguard Fiduciary Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Vanguard Fiduciary Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351M Sell
563,711
-6,229
-1% -$4.24M 0.08% 224
2026
Q1 		$440M Buy
+569,940
New +$436M 0.11% 159

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vanguard Fiduciary Trust's REGN Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 1.1% in Q2 2026, selling an estimated $4.24M and leaving 563,711 shares worth $351M. The position accounts for 0.08% of the portfolio, ranked #224.

Vanguard Fiduciary Trust first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $440M in Q1 2026. 1,318 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Vanguard Fiduciary Trust held 563,711 shares of Regeneron Pharmaceuticals worth $351M as of Q2 2026.
  • Vanguard Fiduciary Trust sold 6,229 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.24M.
  • Regeneron Pharmaceuticals made up 0.08% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #224 holding.
  • Vanguard Fiduciary Trust first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Regeneron Pharmaceuticals position peaked at $440M in Q1 2026.
  • 1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.